Latest Commercialization News

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Intelligent Monitoring Group Limited has reaffirmed its FY25 adjusted EBITDA guidance above $38 million, reporting a robust $7.9 million operating cash flow for the first half of 2025. The company is advancing its strategic acquisitions and launching innovative video guarding services poised to disrupt the security sector.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.

NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Clever Culture Systems Ltd has achieved a key cashflow break-even milestone in Q4 2024, driven by strong sales growth from major pharmaceutical clients including AstraZeneca and Bristol Myers Squibb. The company is also advancing its product line with a new APAS® Contact Plate capability set for mid-2025 launch.

Condor Energy reports a significant upgrade to its Piedra Redonda gas field resource estimate, highlighting a best estimate contingent resource of 1 trillion cubic feet (Tcf) of gas offshore Peru, supported by advanced seismic reprocessing and new technical insights.